What Did the Human Phase 2 Trial Find?

Get My Book On Amazon: https://a.co/d/avbaV48Download

The Peptide Cheat Sheet: https://peptidecheatsheet.carrd.co/

Download The Bioregulator Cheat Sheet: https://bioregulatorcheatsheet.carrd.co/

1 On 1 Coaching Application: https://hunterwilliamscoaching.carrd.co/

Book A Call With Me: https://hunterwilliamscall.carrd.co/

Supplement Sources: https://hunterwilliamssupplements.carrd.co/

Amazon Storefront: https://www.amazon.com/shop/hunterwilliams/list/WE16G2223BXA?ref_=cm_sw_r_cp_ud_aipsflist_R7QWQC0P1RACB2ETY3DY

Socials:

Instagram: https://www.instagram.com/hunterwilliamscoaching/Podcast: https://hunterwilliamspodcast.buzzsprout.com/

Video Topic Request: https://hunterwilliamsvideotopic.carrd.co/

In today’s video I unpack amlexanox—an old anti-inflammatory/allergy drug with surprising metabolic effects. I share my first encounter with it in the research-chem world, what I noticed subjectively, and then dive into mechanisms (IKKε/TBK1 inhibition, catecholamine resensitization, beige fat), rodent data, the Phase 2 human trial (150 mg/day), safety, dosing, who seems to respond best, and how I’m stacking it inside Bio Ignite. If your goal is fat loss with stubborn adipose inflammation, this is worth understanding.

0:00 - Welcome + what today’s video covers

0:28 - How I first found “AM Lox” browsing catalogs

1:06 - Cycling off SLU-PP-332 and first personal trial

1:40 - Noticing dryness/ab definition; early under-dosing

2:12 - 2025 “sugar diet” + hunting for FGF21 boosters

2:40 - Finding data that amlexanox increases FGF21

3:02 - Literature dosage (100–150 mg) vs my early dose

3:38 - Why I think it’s a useful fat-loss rotation tool

4:24 - Channel/hosting update + where to find my videos

5:08 - Slides start: what amlexanox is/was used for

6:00 - Core mechanism: IKKε/TBK1 → PDE3B → cAMP resistance

7:16 - IL-6→STAT3 hepatic signaling + beigeing via FGF21

8:30 - Big-picture benefits: inflammation, insulin sensitivity, glycemia

10:32 - Human data: Phase 2 trial (150 mg/day x 12 weeks)

11:10 - Modest/variable weight change; who improved most

12:37 - Practical takeaways: glycemia, liver fat, insulin sensitivity

14:12 - Dosing in practice (50 mg caps, TID = 150 mg/day)

15:12 - Responder phenotype: high adipose inflammation

16:00 - Who benefits most + variability at similar body fat

17:56 - Study roll-up and mechanism recap

18:52 - Final thoughts, use-cases, and product note (Bio Ignite)

19:54 - Thank you + where to grab the peptide cheat sheet

What You'll Learn

• Why amlexanox can “release the brakes” on fat-burning by inhibiting IKKε/TBK1 and restoring cAMP/catecholamine responsiveness.

• How it raises IL-6 transiently in adipose, activates STAT3 in the liver, suppresses gluconeogenesis, and increases FGF21 to promote beige fat programs.

• The mouse vs. human gap: robust fat loss in mice; in humans, clearer improvements in A1c, fructosamine, liver fat, insulin sensitivity—especially when adipose inflammation is high.

• Dosing used in the Phase 2 trial: 50 mg TID (total 150 mg/day) for 12 weeks.

• Safety snapshot: no serious AEs attributed to amlexanox in metabolic trials; most common was a transient rash.

Timestamps (exact to the transcript)What you’ll learn